GMP Violations At GSK's Former Puerto Rico Plant Are Basis Of $750 Million DoJ Settlement
This article was originally published in The Pink Sheet Daily
Executive Summary
In the first False Claims Act case alleging cGMP violations the government cites microbial contamination, split tablets and product mix-ups.
You may also be interested in...
Why Baxter’s GMP False Claims Settlement Was Smaller Than Those Of GSK, Ranbaxy
Baxter resolves US plant’s GMP whistleblower allegations for just $18m, a bargain compared to the $750m GlaxoSmithKline paid in 2010 and the $500m Ranbaxy paid in 2013. One reason: it was more narrowly focused.
GMP False Claims Case Falters, But Pharma Isn’t In Clear Yet
First appellate court ruling on the role of good manufacturing practice violations in False Claims Act suits could make future cases tougher, but legal experts still predict a flurry of such suits, with other jurisdictions weighing in. And the Justice Department has its own opinion on the matter.
GMP False Claims Case Falters, But Pharma Isn’t In Clear Yet
First appellate court ruling on the role of good manufacturing practice violations in False Claims Act suits could make future cases tougher, but legal experts still predict a flurry of such suits, with other jurisdictions weighing in. And the Justice Department has its own opinion on the matter.